Striant, a buccal system developed by Auxilium Pharmaceuticals, has become a widely used method of testosterone therapy treatment. This system is innovative in drug administration due to its low maintenance dispersal system. With Striant, a patient attaches the buccal system to the gums or inner cheek where it gradually releases medication for up to 12 hours. Striant is high in demand not only for being so low maintenance but because it is the only one of its kind currently on the market for treatment of low testosterone.
Recent studies have alarmed the U.S. Food and Drug Administration of the safety of these products. As a result of these studies, the FDA announced on January 31, 2014, that they were going to further investigate the related risks and cautioned current and potential users of these side effects.
Studies have been previously published assessing the risks associated with treatment in older users. New data presents information that low T treatment nearly triples the risk of heart attack, myocardial infarction and stroke.
Every year in the United States, over 5 million prescriptions are filled for low testosterone treatments. This data is startling since a recent study also noted that of men undergoing treatment, 43 percent had normal testosterone levels and were unnecessarily placed at risk.
Since the FDA safety announcement in January of 2014, many men have come forward about testosterone related injuries. In June 2014, a multidistrict litigation was created by the federal judicial panel for testosterone cases. Judge Matthew F. Kennelly will oversee the pretrial proceedings for the 175 cases that are already pending in the courts though it is estimated that the case total will exceed a thousand. Current defendants include Abbott, AbbVie, Pfizer, and the makers of Striant, Auxiliium Pharmaceuticals.
Allegations that the company was negligent and greatly undermined the risks of the medication are the basis for their cases. Claims were also made that the company’s marketing campaign was deceiving and convinced consumers that the product was safe to treat the natural signs of aging.
It is predicted that the number of Striant lawsuits will steadily increase as users begin to relate their injuries to treatment. Auxilium Pharmaceuticals also manufacture Testopel and Testim, and are under fire for these products as well.
If you or a loved one has suffered injury such as heart attack, stroke or death after beginning treatment with Striant or like products, contact an experienced attorney who can discuss your legal rights as a consumer.